NASDAQ:

ASTX:

astex™
  • About
  • Pipeline
  • Technology
  • Partners
  • Investors
  • Contact
  • Mission & Values
  • Leadership Team
  • Scientific Advisory Board
  • Careers
  • Products
  • Clinical Trials
  • Scientific and Partnering Events
  • Presentations and Publications
  • Pyramid™ Platform
  • AstexViewer™
  • Corporate Partnerships
  • Intellectual Property
  • Events Calendar
  • Stock Information
  • Corporate Governance
  • Board Committees
  • SEC Filings
  • Press Releases
  • Investor FAQs
  • Annual Reports
  • Investor Kit
  • Email Alerts
  • in the news
  • upcoming events
  • 23-25 May 2013

    BIT’s 2nd Annual International...

  • 26-29 May 2013

    4th International Symposium on...

see all scientific and partnering events →

product pipeline

AT7519 – CDK inhibitor (MM)

— in phase 2 clinical trial

AT13387 – HSP90 inhibitor (GIST, Prostate & Lung)

— in phase 2 clinical trial

Amuvatinib/MP470 (SCLC)

— in phase 2 clinical trial

SGI110 – DNMT inhibitor (MDS, AML, Ovarian & Liver)

— in phase 2 clinical trial
see all pipeline products →

receive investor updates

Get automatic financial updates and information from NASDAQ.

sign up for email alerts →

Corporate Partnerships

  • AstraZeneca logo. Click here for more information about this partner.
  • Eisai logo. Click here for more information about this partner.
  • gsk logo. Click here for more information about this partner.
  • Janssen logo. Click here for more information about this partner.
  • Novartis logo. Click here for more information about this partner.

©2012 Astex Pharmaceuticals. All rights reserved.

  • Forward-Looking Statement
  • Site Map
  • Privacy Policy
  • Terms of Use

Astex Pharmaceuticals, Inc.™

4140 Dublin Blvd., Suite 200, Dublin, CA 94568, USA